Therapeutic Benefits of Psilocybin

Judy Blumstock

Judy Blumstock has over 25 years of venture capital and private equity experience spanning early to late-stage investment in life science and biotechnology. Judy spent more than ten years as the executive director of corporate development for Toronto Innovation Acceleration Partners (TIAP). She has held senior roles at Genesys Capital, RBC Capital Partners, and Drug Royalty Corporation (now DRI Capital Inc.), where she served as the director of biological and pharmaceutical research. Judy brings these experiences to her role as CEO of Diamond Therapeutics, a psychedelic drug development company focused on broadly accessible, low-dose therapies for mental health.